



SNS COLLEGE OF ALLIED HEALTH SCIENCE
SNS Kalvi Nagar, Coimbatore - 35
Affiliated to Dr MGR Medical University, Chennai



DEPARTMENT OF OPERATION THEATRE AND ANAESTHESIA TECHNOLOGY - II YEAR

COURSE NAME: PHARMACOLOGY

TOPIC - ANTIEMETICS

MRS.GAYATHIRI.K
Lecturer



ANTIEMETICS



Definition

Antiemetics : Medications that prevent or alleviate nausea and vomiting by acting on various receptors and pathways in the central nervous system (CNS) and gastrointestinal (GI) tract involved in the vomiting reflex.



ANTIEMETICS



Mechanism of Action

Ondansetron (5-HT₃ Receptor Antagonist)

- Blocks serotonin (5-HT₃) receptors in the chemoreceptor trigger zone (CTZ) of the brain and vagal afferents in the GI tract, inhibiting nausea and vomiting signals.

Metoclopramide (Dopamine D₂ Receptor Antagonist & Pro kinetic)

- Antagonizes dopamine D₂ receptors in the CTZ.
- Enhances gastric motility and accelerates gastric emptying by stimulating 5-HT₄ receptors and inhibiting 5-HT₃ receptors in the GI tract.

Promethazine (H₁ Receptor Antagonist & Anticholinergic)

- Blocks histamine H₁ receptors in the vestibular system and CTZ.
- Exhibits anticholinergic effects, reducing stimulation of the vomiting center via muscarinic receptors.

Dexamethasone (Corticosteroid):

Exact antiemetic mechanism unclear; likely reduces inflammation in the CTZ, modulates neurotransmitter release, and inhibits prostaglandin synthesis.



ANTIEMETICS

Pharmacodynamics

Ondansetron

- Selectively inhibits 5-HT₃ receptors, reducing nausea and vomiting triggered by chemotherapy, radiotherapy, or postoperative states.
- Minimal effect on other neurotransmitter systems, leading to fewer CNS side effects.

Metoclopramide

- Acts on dopamine and serotonin pathways to reduce nausea and enhance GI motility.
- May cause CNS effects due to dopamine antagonism.

Promethazine

- Broad action on histamine, muscarinic, and dopamine receptors, providing antiemetic and sedative effects.
- Effective for motion sickness and postoperative nausea due to vestibular and histamine receptor blockade.

Dexamethasone:

Modulates inflammatory pathways and neurotransmitter activity in the CTZ.

Potentiates antiemetic effects of 5-HT₃ antagonists and NK1 antagonists, particularly in CINV and PONV.

Provides prolonged antiemetic action due to its long half-life.



ANTIEMETICS



Pharmacokinetics

Ondansetron

Onset of Action: 30 minutes (oral), 10–15 minutes (IV), 15–30 minutes (IM).

.Duration of Action.: 4–8 hours.

.Absorption.: Well-absorbed orally

.Metabolism.: Extensively metabolized in the

.Excretion.: Primarily renal

.Dosage (IM).: 4–8 mg every 4–8 hours as needed (adults);
pediatric doses vary by weight (0.1 mg/kg).

-



ANTIEMETICS



.Metoclopramide:

- .Onset of Action.: 30–60 minutes (oral), 1–3 minutes (IV), 10–15 minutes (IM).
- .Duration of Action.: 1–2 hours.
- .Absorption.: High oral
- .Metabolism.: Hepatic
- .Excretion.: Primarily renal
- .Dosage (IM).: 10 mg every 4–6 hours as needed (adults).



ANTIEMETICS



Promethazine:

- .Onset of Action.: 20 minutes (oral), 5–10 minutes (IV), 15–20 minutes (IM).
- .Duration of Action.: 4–6 hours
- .Absorption.: Well-absorbed orally
- .Metabolism.: Hepatic
- .Excretion.: Primarily renal, some biliary.
- .Dosage (IM).: 12.5–25 mg every 4–6 hours as needed (adults).



ANTIEMETICS



Dexamethasone:

Onset of Action: 1–2 hours (oral/IV/IM).

Duration of Action: 36–72 hours

Absorption: Well-absorbed orally

Metabolism: Hepatic

Excretion: renal

Dosage (IM): 4–8 mg single dose for PONV or CINV (adults); may repeat every 6–12 hours as needed; pediatric: 0.1–0.2 mg/kg.



ANTIEMETICS



Indications.

Ondansetron:

- Chemotherapy-induced nausea and vomiting (CINV).
- Radiotherapy-induced nausea and vomiting (RINV).
- Postoperative nausea and vomiting (PONV).

Metoclopramide:

- PONV, CINV.
- Gastroparesis and gastroesophageal reflux disease (GERD) due to prokinetic effects.

Promethazine:

- Motion sickness, PONV, Allergic conditions (adjunctive therapy due to antihistamine effects).

Dexamethasone:

CINV (especially in combination with 5-HT₃ antagonists).

PONV (prophylaxis and treatment).

Nausea/vomiting associated with acute infections or inflammation.



Contraindications.

Ondansetron:

- Hypersensitivity to 5-HT₃ antagonists.
- Concomitant use with apomorphine (risk of profound hypotension and loss of consciousness).
- Congenital long QT syndrome (risk of torsades de pointes).

Metoclopramide:

- GI obstruction, perforation, or hemorrhage (due to prokinetic effects).
- Pheochromocytoma (risk of hypertensive crisis).
- History of tardive dyskinesia or extrapyramidal symptoms (EPS).
- Seizure disorders.

Promethazine:

- Hypersensitivity to phenothiazines.
- Children under 2 years (risk of respiratory depression).
- Coma or severe CNS depression.
- Glaucoma, prostatic hypertrophy (due to anticholinergic effects).

Dexamethasone:

Hypersensitivity to corticosteroids.

Active systemic fungal infections.

Recent live virus vaccination (immunosuppression risk).

Peptic ulcer disease or uncontrolled diabetes (with caution).

ANTIEMETICS



Side Effects.

ANTIEMETICS



Ondansetron:

- Common: Headache, constipation, fatigue.
- Less Common: Dizziness, diarrhea, rash.

Metoclopramide:

- Common: Drowsiness, fatigue, diarrhea.
- Less Common: Restlessness, agitation, EPS (e.g., dystonia, akathisia).

Promethazine:

- Common: Sedation, dry mouth, blurred vision.
- Less Common: Confusion, urinary retention, hypotension.

Dexamethasone:

Common: Insomnia, increased appetite, hyperglycemia.

Less Common: Mood changes, GI irritation, hypertension



ANTIEMETICS



Adverse Effects.

Ondansetron:

- QT prolongation and risk of arrhythmias (rare, dose-dependent).
- Serotonin syndrome (if combined with other serotonergic drugs).

Metoclopramide:

- Tardive dyskinesia (potentially irreversible, especially with prolonged use).
- Neuroleptic malignant syndrome (rare).
- Hyperprolactinemia (galactorrhea, gynecomastia).

Promethazine:

- Severe respiratory depression (especially in children).
- Tissue necrosis with IV administration (if extravasation occurs).
- Cholestatic jaundice (rare).

Dexamethasone:

Adrenal suppression (with prolonged use).

Increased infection risk (immunosuppression).

Osteoporosis, myopathy, or psychosis (long-term, high-dose).



- .Ondansetron. is frequently mentioned across the provided question papers (e.g., [LP 0819], [LQ 0220]) as a key antiemetic for PONV and CINV.
Dexamethasone. is noted as an antiemetic, particularly in the context of chemotherapy and postoperative settings ([LK 0217]).



THANK YOU